Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","amount":"$396.0 million","upfrontCash":"$130.0 million","newsHeadline":"Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"OmniAb","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA\u2019s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces that Janssen Has Received Approval from U.S. FDA for Tecvayli\u2122 (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces that Janssen Has Received Approval from European Commission for Tecvayli\u00ae (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Completion of OmniAb Spin-Off","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by OmniAb

    Menu

    OmniAb

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OmniAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ligand Announces Completion of OmniAb Spin-Off

              Details:

              For the last decade, Ligand has been focused on providing the tools and technologies needed by the pharmaceutical industry and sharing in the promise of drug innovation with the shareholders.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Demerger November 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OmniAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ligand Announces that Janssen Has Received Approval from U.S. FDA for Tecvayli™ (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple Myeloma

              Details:

              Tecvayli (teclistamab) is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists using OmniAb’s OmniRat antibody discovery technology.

              Lead Product(s): Teclistamab-cqyv

              Therapeutic Area: Oncology Product Name: Tecvayli

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OmniAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

              Details:

              Under the terms of the agreement, Talem will oversee the development and optimization of the antibodies for each program. OmniAb and Talem will share downstream economics upon potential out-licensing or commercialization of the OmniChicken-derived antibody.

              Lead Product(s): OmniChicken-derived Antibody

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Recipient: Talem Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OmniAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ligand Announces that Janssen Has Received Approval from European Commission for Tecvayli® (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple...

              Details:

              Tecvayli (teclistamab) is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists using OmniAb’s OmniRat antibody discovery technology.

              Lead Product(s): Teclistamab-cqyv

              Therapeutic Area: Oncology Product Name: Tecvayli

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OmniAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

              Details:

              Ligand’s OmniAb antibody discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Avista Public Acquisition Corp. II

              Deal Size: $396.0 million Upfront Cash: $130.0 million

              Deal Type: Merger March 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY